Non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention group: Intervention group: In the intervention group, in addition to lifestyle education, 12 mg astaxanthin capsules were given orally twice daily, 1 capsule each time, for 8 weeks..
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to 80 Years
Inclusion criteria
Inclusion criteria: Major conditions for inclusion in the study before randomization: - Ultrasound report of fatty liver grade 1 and 2, increased ALT enzyme >40, increased AST enzyme <38, age between 12 and 80 years. Major conditions for not including in the study before randomization: Patient's unwillingness to participate in the pregnancy and breastfeeding plan, use of anticoagulant drugs, thyroid diseases, spleen disease, cirrhosis, viral hepatitis, or obstructive liver diseases, dyslipidemias under treatment, - Overt diabetes, pulmonary diseases, use of any medication that affects liver metabolism and enzymes, including oral contraceptives, corticosteroids, salazines.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparing the effect of astaxanthin capsules on the liver enzyme ALT (alanine transaminase) with placebo in patients with non-alcoholic fatty liver disease. Timepoint: at baseline( before the start of the intervention) and after 8 weeks of treatment. Method of measurement: Using a liver enzyme kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahsa SAbernavaei
Iran University of Medical Sciences
Outcome results
None listed